Isoproterenol Hydrochloride

(Isoproterenol)

Phase 1Small molecule

Isoproterenol Hydrochloride is one of 92 small molecule programs targeting Anorexia Nervosa. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Anorexia NervosaActive, not recruiting

TachycardiaActive, not recruiting

ESSCompleted

AdjuvantRecruiting

Blood PressureCompleted

HfpefCompleted

Anorexia NervosaPreclinical

Active, not recruiting

TachycardiaPreclinical

Active, not recruiting

ESSPreclinical

Completed

AdjuvantPhase 1

Recruiting

Blood PressurePreclinical

Completed

HfpefPreclinical

Completed

Competition

Competitive Landscape

56 competitors in ESS

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

7 2

Proamatine

Takeda

Approved

2 3

Quviviq

Idorsia Pharmaceuticals Ltd.

Approved

1 4

Opdualag

Bristol-Myers Squibb

Phase 2

2 5

Opdivo

Bristol-Myers Squibb

Phase 2

2 6

Darzalex

Johnson & Johnson

Phase 2

1 7

Decadron

AAspen Global Incorporated

Phase 2

1 8

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

1 9

Kyprolis

VVirionyx Corporation Limited

Phase 2

1 10

Mineral Trioxide Aggregate

JJordan University of Science and Technology

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Obesity

NCT05219799

Q4 2027

Recruiting

Study completion

NCT02673996

Q2 2028

Phase 1Recruiting

Aging

NCT06520982

Q4 2028

Phase 1Recruiting

Adjuvant

NCT06643221

Clinical

Trials by Indication[1]

Anorexia Nervosa2 trials

Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa

Completed·LLaureate Institute for Brain Research, Inc.·N/A·NCT02615119·97 enrolled

Augmented Interoceptive Exposure Training in Anorexia Nervosa

Unknown status·LLaureate Institute for Brain Research, Inc.·N/A·NCT03019081·25 enrolled

ESS2 trials

Measurement of Bispectral Index and Awareness in Patients Undergoing Electrophysiology Studies With Isoproterenol

Completed·NNYU Langone Health·N/A·NCT01377636·20 enrolled

Pharmacological Modulation of the Intrarenal Pressure During Endourological Procedures in the Upper Urinary Tract

Completed·FFredericia Hosptial·Phase 2/3·NCT00428428·12 enrolled

Tachycardia1 trial

Autoimmune Basis for Postural Tachycardia Syndrome

Enrolling by invitation·VVanderbilt University Medical Center·N/A·NCT02725060·58 enrolled

Kidney Stone1 trial

Retrograde Intrarenal Stone Surgery - A Method of Treating the ESWL Resistant Kidney Stone

Unknown status·FFredericia Hosptial·Phase 2·NCT00323843·10 enrolled

HFpEF1 trial

Chronotropic Incompetence in Patients With HFpEF

Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT02524145·40 enrolled

6 more indications

Aging1 trial

Early Neurovascular Adaptations in Aging Women

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT06520982·64 enrolled

Adjuvant1 trial

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

Recruiting·UUniversity of Arizona·Phase 1·NCT06643221·100 enrolled

Paroxysmal atrial fibrillation1 trial

Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation

Completed·UUniversity of Michigan·Phase 2·NCT03032965·131 enrolled

Blood Pressure1 trial

Decision Support for Intraoperative Low Blood Pressure

Completed·VVanderbilt University Medical Center·N/A·NCT02726620·22,435 enrolled

Obesity1 trial

Sex Disparities in Hypoxic Vasodilation and Impact of Obesity

Recruiting·UUniversity of Missouri-Columbia·Phase 1·NCT05219799·72 enrolled

Unspecified2 trials

Vascular Response to Isoproterenol and β2 Adrenergic Receptor Polymorphisms

Completed·HHadassah Medical Organization·N/A·NCT00226551·100 enrolled

POTS Adrenergic Ab (CIHR Aims #1&2)

Recruiting·UUniversity of Calgary··NCT02673996·125 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

ISOPROTERENOL HYDROCHLORIDE

NDA NDA010375

Jan 1, 1982

ISUPREL

NDA NDA011178

Jan 1, 1982

NORISODRINE AEROTROL

NDA NDA016814

Jan 1, 1982

ISUPREL

NDA NDA010515

Jan 1, 1982

NORISODRINE

NDA NDA006905

Jan 1, 1982

AEROLONE

NDA NDA007245

Jan 1, 1982

ISUPREL

NDA NDA006327

Jan 1, 1982

VAPO-ISO

NDA NDA016813

Jan 1, 1982

ISUPREL

NDA NDA006328

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Isoproterenol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isoproterenol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isoproterenol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA010375). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Sanofi

Isoproterenol Hydrochloride

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Anorexia Nervosa2 trials

ESS2 trials

Tachycardia1 trial

Kidney Stone1 trial

HFpEF1 trial

Aging1 trial

Adjuvant1 trial

Paroxysmal atrial fibrillation1 trial

Blood Pressure1 trial

Obesity1 trial

Unspecified2 trials

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News